Shares of Baxter International Inc. (NYSE:BAX – Get Free Report) have earned an average rating of “Hold” from the fourteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $51.07.
A number of equities research analysts recently issued reports on the company. KeyCorp lowered their price objective on Baxter International from $53.00 to $51.00 and set an “overweight” rating on the stock in a research note on Monday, July 31st. Citigroup dropped their price target on shares of Baxter International from $47.00 to $45.00 and set a “neutral” rating on the stock in a research note on Monday, August 21st. Stifel Nicolaus lifted their price objective on shares of Baxter International from $54.00 to $56.00 in a research note on Wednesday, July 12th. StockNews.com started coverage on Baxter International in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Finally, Barclays reduced their price target on Baxter International from $58.00 to $54.00 and set an “overweight” rating for the company in a research report on Monday, July 31st.
Institutional Trading of Baxter International
Baxter International Stock Down 2.6 %
Baxter International stock opened at $40.60 on Friday. The company has a market capitalization of $20.56 billion, a PE ratio of -7.17, a PEG ratio of 2.95 and a beta of 0.60. Baxter International has a 12-month low of $37.35 and a 12-month high of $60.39. The firm’s fifty day moving average is $44.57 and its 200 day moving average is $42.87. The company has a quick ratio of 0.92, a current ratio of 1.42 and a debt-to-equity ratio of 2.54.
Baxter International (NYSE:BAX – Get Free Report) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.04). The firm had revenue of $3.71 billion for the quarter, compared to the consensus estimate of $3.79 billion. Baxter International had a negative net margin of 19.00% and a positive return on equity of 24.94%. As a group, sell-side analysts predict that Baxter International will post 2.55 EPS for the current fiscal year.
Baxter International Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be given a dividend of $0.29 per share. The ex-dividend date is Thursday, August 31st. This represents a $1.16 dividend on an annualized basis and a yield of 2.86%. Baxter International’s dividend payout ratio (DPR) is presently -20.49%.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
- Five stocks we like better than Baxter International
- How Can Investors Benefit From After-Hours Trading
- 3 Takeaways from the August Inflation Report
- How to Evaluate a Stock Before Buying
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- How to Calculate Stock Profit
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.